Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group

The designation “clinically localized prostate cancer” comprises a group of biologically heterogeneous tumours with different growth rates and risks of relapse. Because prostate cancer is primarily a disease of older men, treatment selection must take into account the prognosis of the tumour, patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Parulekar, W.R., McKenzie, M., Chi, K.N., Klotz, L., Catton, C., Brundage, M., Ding, K., Hiltz, A., Meyer, R., Saad, F.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2008
Materias:
Canadian Centre Activities
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528309/
https://www.ncbi.nlm.nih.gov/pubmed/18769611
_version_ 1782158878304108544
author Parulekar, W.R.
McKenzie, M.
Chi, K.N.
Klotz, L.
Catton, C.
Brundage, M.
Ding, K.
Hiltz, A.
Meyer, R.
Saad, F.
author_facet Parulekar, W.R.
McKenzie, M.
Chi, K.N.
Klotz, L.
Catton, C.
Brundage, M.
Ding, K.
Hiltz, A.
Meyer, R.
Saad, F.
author_sort Parulekar, W.R.
collection PubMed
description The designation “clinically localized prostate cancer” comprises a group of biologically heterogeneous tumours with different growth rates and risks of relapse. Because prostate cancer is primarily a disease of older men, treatment selection must take into account the prognosis of the tumour, patient age, comorbidities, side effects of treatment, and patient preferences. Clinical trials must identify the various prognostic groups and test the appropriate treatment strategies within these subgroups.
format Text
id pubmed-2528309
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-25283092008-09-03 Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group Parulekar, W.R. McKenzie, M. Chi, K.N. Klotz, L. Catton, C. Brundage, M. Ding, K. Hiltz, A. Meyer, R. Saad, F. Curr Oncol Canadian Centre Activities The designation “clinically localized prostate cancer” comprises a group of biologically heterogeneous tumours with different growth rates and risks of relapse. Because prostate cancer is primarily a disease of older men, treatment selection must take into account the prognosis of the tumour, patient age, comorbidities, side effects of treatment, and patient preferences. Clinical trials must identify the various prognostic groups and test the appropriate treatment strategies within these subgroups. Multimed Inc. 2008-08 /pmc/articles/PMC2528309/ /pubmed/18769611 Text en 2008 Multimed Inc.
spellingShingle Canadian Centre Activities
Parulekar, W.R.
McKenzie, M.
Chi, K.N.
Klotz, L.
Catton, C.
Brundage, M.
Ding, K.
Hiltz, A.
Meyer, R.
Saad, F.
Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group
title Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group
title_full Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group
title_fullStr Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group
title_full_unstemmed Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group
title_short Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group
title_sort defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the national cancer institute of canada clinical trials group
topic Canadian Centre Activities
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528309/
https://www.ncbi.nlm.nih.gov/pubmed/18769611
work_keys_str_mv AT parulekarwr definingtheoptimaltreatmentstrategyforlocalizedprostatecancerpatientsasurveyofongoingstudiesatthenationalcancerinstituteofcanadaclinicaltrialsgroup
AT mckenziem definingtheoptimaltreatmentstrategyforlocalizedprostatecancerpatientsasurveyofongoingstudiesatthenationalcancerinstituteofcanadaclinicaltrialsgroup
AT chikn definingtheoptimaltreatmentstrategyforlocalizedprostatecancerpatientsasurveyofongoingstudiesatthenationalcancerinstituteofcanadaclinicaltrialsgroup
AT klotzl definingtheoptimaltreatmentstrategyforlocalizedprostatecancerpatientsasurveyofongoingstudiesatthenationalcancerinstituteofcanadaclinicaltrialsgroup
AT cattonc definingtheoptimaltreatmentstrategyforlocalizedprostatecancerpatientsasurveyofongoingstudiesatthenationalcancerinstituteofcanadaclinicaltrialsgroup
AT brundagem definingtheoptimaltreatmentstrategyforlocalizedprostatecancerpatientsasurveyofongoingstudiesatthenationalcancerinstituteofcanadaclinicaltrialsgroup
AT dingk definingtheoptimaltreatmentstrategyforlocalizedprostatecancerpatientsasurveyofongoingstudiesatthenationalcancerinstituteofcanadaclinicaltrialsgroup
AT hiltza definingtheoptimaltreatmentstrategyforlocalizedprostatecancerpatientsasurveyofongoingstudiesatthenationalcancerinstituteofcanadaclinicaltrialsgroup
AT meyerr definingtheoptimaltreatmentstrategyforlocalizedprostatecancerpatientsasurveyofongoingstudiesatthenationalcancerinstituteofcanadaclinicaltrialsgroup
AT saadf definingtheoptimaltreatmentstrategyforlocalizedprostatecancerpatientsasurveyofongoingstudiesatthenationalcancerinstituteofcanadaclinicaltrialsgroup

Ejemplares similares